Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 20Head & Neck 2Gynecologic 2Breast 2Thoracic 1Plasma cell 1Other neoplasm 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Breast Neoplasms 84Triple Negative Breast Neoplasms 24Neoplasm Metastasis 9Breast Neoplasms, Male 8Carcinoma, Intraductal, Noninfiltrating 7Pancreatic Neoplasms 5Ovarian Neoplasms 5Melanoma 5Colorectal Neoplasms 5Breast Carcinoma In Situ 5Uterine Cervical Neoplasms 4Prostatic Neoplasms 4Inflammatory Breast Neoplasms 4Endometrial Neoplasms 4Urinary Bladder Neoplasms 3Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Salivary Gland Neoplasms 3Esophageal Neoplasms 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Anatomic Stage IV Breast Cancer AJCC v8 3Thyroid Neoplasms 2Skin Neoplasms 2Sarcoma 2Rectal Neoplasms 2Neoplasms 2Multiple Myeloma 2Lymphoma 2Lung Neoplasms 2

Interventions

Early Intervention, Educational 5Radiotherapy 4Psychiatric Rehabilitation 4Capecitabine 4pembrolizumab 3Trastuzumab 3Methods 3Magnetic Resonance Spectroscopy 3Irinotecan 3Gemcitabine 3Counseling 3trametinib 2palbociclib 2cediranib 2Standard of Care 2Mental Status and Dementia Tests 2Fluorodeoxyglucose F18 2Docetaxel 2Cyclophosphamide 2Biopsy 22,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 2veliparib 1ulixertinib 1trastuzumab biosimilar HLX02 1tipifarnib 1spartalizumab 1sargramostim 1sapanisertib 1relatlimab 1pertuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Rectal Neoplasms × Biopsy × Breast × Clear all
NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT00369109 2013-04-08

Skin Biopsies and DNA Analysis in Patients Receiving Irinotecan or Gemcitabine For Advanced Solid Tumors

Barbara Ann Karmanos Cancer Institute

Completed
60 enrolled
BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡